145 related articles for article (PubMed ID: 35864224)
1. Aggressive immunotherapy combined with bortezomib and rituximab for membranous nephropathy associated with enzyme replacement therapy in Pompe disease.
Sasaki K; Uchimura T; Inaba A; Otani M; Hanakawa J; Ito S
Pediatr Nephrol; 2023 Mar; 38(3):921-925. PubMed ID: 35864224
[TBL] [Abstract][Full Text] [Related]
2. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B
J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884
[TBL] [Abstract][Full Text] [Related]
3. Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy.
Chen HA; Hsu RH; Fang CY; Desai AK; Lee NC; Hwu WL; Tsai FJ; Kishnani PS; Chien YH
Front Immunol; 2024; 15():1336599. PubMed ID: 38715621
[TBL] [Abstract][Full Text] [Related]
4. An updated management approach of Pompe disease patients with high-sustained anti-rhGAA IgG antibody titers: experience with bortezomib-based immunomodulation.
Desai AK; Shrivastava G; Grant CL; Wang RY; Burt TD; Kishnani PS
Front Immunol; 2024; 15():1360369. PubMed ID: 38524130
[TBL] [Abstract][Full Text] [Related]
5. Antibodies against recombinant human alpha-glucosidase do not seem to affect clinical outcome in childhood onset Pompe disease.
van Kooten HA; Ditters IAM; Hoogeveen-Westerveld M; Jacobs EH; van den Hout JMP; van Doorn PA; Pijnappel WWMP; van der Ploeg AT; van der Beek NAME
Orphanet J Rare Dis; 2022 Feb; 17(1):31. PubMed ID: 35109913
[TBL] [Abstract][Full Text] [Related]
6. Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease.
Hunley TE; Corzo D; Dudek M; Kishnani P; Amalfitano A; Chen YT; Richards SM; Phillips JA; Fogo AB; Tiller GE
Pediatrics; 2004 Oct; 114(4):e532-5. PubMed ID: 15466083
[TBL] [Abstract][Full Text] [Related]
7. Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort.
Desai AK; Baloh CH; Sleasman JW; Rosenberg AS; Kishnani PS
Front Immunol; 2020; 11():1727. PubMed ID: 32849613
[TBL] [Abstract][Full Text] [Related]
8. Are Anti-rhGAA Antibodies a Determinant of Treatment Outcome in Adults with Late-Onset Pompe Disease? A Systematic Review.
Ditters IAM; van Kooten HA; van der Beek NAME; van der Ploeg AT; Huidekoper HH; van den Hout JMP
Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759814
[TBL] [Abstract][Full Text] [Related]
9. Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease.
Cousens LP; Mingozzi F; van der Marel S; Su Y; Garman R; Ferreira V; Martin W; Scott DW; De Groot AS
Hum Vaccin Immunother; 2012 Oct; 8(10):1459-64. PubMed ID: 23095864
[TBL] [Abstract][Full Text] [Related]
10. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.
Messinger YH; Mendelsohn NJ; Rhead W; Dimmock D; Hershkovitz E; Champion M; Jones SA; Olson R; White A; Wells C; Bali D; Case LE; Young SP; Rosenberg AS; Kishnani PS
Genet Med; 2012 Jan; 14(1):135-42. PubMed ID: 22237443
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Experience with Anaphylaxis and Desensitization to Alglucosidase Alfa in Pompe Disease.
Ertoy Karagol HI; Inci A; Terece SP; Kilic A; Demir F; Yapar D; Koken G; Okur I; Ezgu FS; Tumer L; Bakirtas A;
Int Arch Allergy Immunol; 2023; 184(4):370-375. PubMed ID: 36623499
[TBL] [Abstract][Full Text] [Related]
12. A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease.
Han SO; Pope R; Li S; Kishnani PS; Steet R; Koeberl DD
Mol Genet Metab; 2016 Feb; 117(2):114-9. PubMed ID: 26454691
[TBL] [Abstract][Full Text] [Related]
13. Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.
Masat E; Laforêt P; De Antonio M; Corre G; Perniconi B; Taouagh N; Mariampillai K; Amelin D; Mauhin W; Hogrel JY; Caillaud C; Ronzitti G; Puzzo F; Kuranda K; Colella P; Mallone R; Benveniste O; Mingozzi F;
Sci Rep; 2016 Nov; 6():36182. PubMed ID: 27812025
[TBL] [Abstract][Full Text] [Related]
14. Assessing the Role of Anti rh-GAA in Modulating Response to ERT in a Late-Onset Pompe Disease Cohort from the Italian GSDII Study Group.
Filosto M; Cotti Piccinelli S; Ravaglia S; Servidei S; Moggio M; Musumeci O; Donati MA; Pegoraro E; Di Muzio A; Maggi L; Tonin P; Marrosu G; Sancricca C; Lerario A; Sacchini M; Semplicini C; Bozzoni V; Telese R; Bonanno S; Piras R; Maioli MA; Ricci G; Vercelli L; Galvagni A; Gallo Cassarino S; Caria F; Mongini T; Siciliano G; Padovani A; Toscano A
Adv Ther; 2019 May; 36(5):1177-1189. PubMed ID: 30879255
[TBL] [Abstract][Full Text] [Related]
15. Immune responses and hypercoagulation in ERT for Pompe disease are mutation and rhGAA dose dependent.
Nayak S; Doerfler PA; Porvasnik SL; Cloutier DD; Khanna R; Valenzano KJ; Herzog RW; Byrne BJ
PLoS One; 2014; 9(6):e98336. PubMed ID: 24897114
[TBL] [Abstract][Full Text] [Related]
16. High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient.
Rairikar M; Kazi ZB; Desai A; Walters C; Rosenberg A; Kishnani PS
Mol Genet Metab; 2017 Sep; 122(1-2):76-79. PubMed ID: 28648664
[TBL] [Abstract][Full Text] [Related]
17. [Enzyme replacement therapy in a patient with Pompe disease].
Fujikawa Y; Kinoshita S; Miyamoto Y; Nakayama T; Endo Y; Sasaki M
No To Hattatsu; 2007 Sep; 39(5):383-6. PubMed ID: 17879614
[TBL] [Abstract][Full Text] [Related]
18. Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease.
Han SO; Li S; Bird A; Koeberl D
Hum Gene Ther; 2015 Nov; 26(11):743-50. PubMed ID: 26417913
[TBL] [Abstract][Full Text] [Related]
19. Mapping the T helper cell response to acid α-glucosidase in Pompe mice.
Nayak S; Sivakumar R; Cao O; Daniell H; Byrne BJ; Herzog RW
Mol Genet Metab; 2012 Jun; 106(2):189-95. PubMed ID: 22494547
[TBL] [Abstract][Full Text] [Related]
20. The pharmacological chaperone AT2220 increases recombinant human acid α-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease.
Khanna R; Flanagan JJ; Feng J; Soska R; Frascella M; Pellegrino LJ; Lun Y; Guillen D; Lockhart DJ; Valenzano KJ
PLoS One; 2012; 7(7):e40776. PubMed ID: 22815812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]